Kontrol-ing COVID-19 As Solutions Progress

Kontrol-ing COVID-19 As Solutions Progress

Nov 11, 2020 | KNR

Prior Report Recap In Sophic Capital’s Promising COVID-19 News, But Health Threat Remains report, we discussed: Recent advances in the battle against COVID-19 that propelled the markets higher; An examination of Pfizer/BioNTech’s phase 3 vaccine trials, and why...
KNR: Promising Vaccine News, But Health Threat Remains

KNR: Promising Vaccine News, But Health Threat Remains

Nov 10, 2020 | KNR

Recent Advances in the Battle Against COVID-19 The world breathed a collective sigh of relief at Pfizer and BioNTech’s announcement of a COVID-19 vaccine candidate passing phase 3 trials. In response, the markets roared on November 9, 2020 with a massive rotation from...
KNR: Keeping Students, Teachers and Families Safe from COVID-19

KNR: Keeping Students, Teachers and Families Safe from COVID-19

Sep 11, 2020 | KNR

—Kontrol BioCloud is a Safe Space Technology™— COVID-19 Mortality in Children is Low, But Long-Term Health Issues Can Persist The coronavirus pandemic has wreaked havoc on our lives, livelihoods, and economies. Worse, one million people have died from...
KNR: A Second Line of Defense Against COVID-19

KNR: A Second Line of Defense Against COVID-19

Aug 11, 2020 | KNR

The Bridge to A Vaccine or Treatment COVID-19 Vaccine Hype a ‘Grave Disservice’ to the Public “Grave Disservice” are the words of Merck & Co (NYSE:MRK) CEO Ken Frazier, during a July 2020 interview with Harvard Business School. We at Sophic...